ClinicalTrialsFinder
RecruitingPhase 3NCT04382846

Novel Regimens in COVID-19 Treatment

Nitazoxanide in Treatment of COVID-19

Sponsor

Tanta University

Enrollment

160 participants

Start Date

May 8, 2020

Study Type

INTERVENTIONAL

Conditions

COVIDCorona Virus Infection

Summary

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Nitazoxanide for people with covid and corona virus infection. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNitazoxanide

Nitazoxanide

Locations(2)

Tanta University, Assiut University

Tanta, Egypt

Sherief Abd-Elsalam

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04382846

Related Trials

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

NCT043621501 location

The Effects of Endotracheal Suctioning on Pain and Serum Markers

NCT066924001 location

Assessment of Chilbains Occuring During Covid-19 Infection

NCT043441191 location

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

NCT0491026966 locations

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

NCT045795881 location